AzTrials
AzTrials

CancerNCT07550192

Oncology Acute Care Follow-up Intervention Study

A study testing Follow-up messaging in people with Cancer, run by University of Texas Southwestern Medical Center at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This pragmatic randomized controlled study evaluates an education intervention designed to increase patient engagement with Oncology Acute Care (OAC) services among patients being treated for cancer at Parkland Health. Eligible patients will be randomized to either a control (usual care) arm or an intervention arm. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cancer
What is being tested?
Follow-up messaging
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteUnited States
Study dates
1 Sep 2026to 31 Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years.
  • Active cancer diagnosis
  • Actively receiving chemotherapy treatment
  • ED Arrival within 30 days of chemotherapy treatment
  • Discharged home following ED visit, observation, or inpatient stay
  • Enrolled in MyChart with valid mobile number and language preference recorded (English or Spanish)

Who cannot join

  • Not enrolled in MyChart or lacking a valid mobile phone number.
  • Language preference not recorded or not English/Spanish (if messaging is only available in these languages).
  • Receiving hospice or palliative care services, where acute symptom management goals may differ.
  • Patients admitted directly to inpatient care without ED visit

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site
  • Parkland Health

    Dallas, Texas, 75235

    Arthur Hong, MD, 214-648-3240, Arthur.Hong@utsouthwestern.edu

    Kathryn Anderson, MA, 214-648-6357, Kathryn.Anderson@utsouthwestern.edu

Other trials in United States

About this study

Official title: A Pragmatic Randomized Controlled Crossover Study to Evaluate the Impact of Messaging Interventions on Emergency Department Utilization Among Oncology Patients at Parkland Health

This pragmatic randomized controlled study evaluates an education intervention designed to increase patient engagement with Oncology Acute Care (OAC) services among patients being treated for cancer at Parkland Health.

Eligible patients will be randomized to either a control (usual care) arm or an intervention arm. If a patient in the control group has experiences a subsequent cancer treatment related ED visit without documented OAC engagement, they will be moved to the intervention arm. Patients in the intervention arm will receive an automated MyChart message and text message within 24 hours of hospital discharge reinforcing oncology acute care (OAC) resources, including contact information for the triage line and guidance for when to seek urgent versus emergency care. Messages will be resent at 48 and 72 hours if unviewed. Once the message is viewed, the patient will enter an outcome tracking period to monitor time to subsequent ED visit or OAC contact. Follow-up will occur in 3-month intervals until an outcome is documented or the study ends.

After randomization, patients will be monitored on an observation list for outcomes including OAC contact and cancer treatment-related Emergency Department (ED) visits. Patients who contact OAC clinic will be removed from observation list and complete the study. We will repeat the observation period and document outcomes if the patient has a subsequent cancer treatment-related ED visits without documented OAC engagement.

Read the detailed description

Overview:

This study is a pragmatic randomized controlled crossover trial designed to evaluate the feasibility and impact of structured follow-up messaging interventions on patient engagement with Oncology Acute Care (OAC) services and reduction in cancer treatment-related Emergency Department (ED) visits at Parkland Health.

Recruitment and Enrollment:

Eligible patients will be identified using an automated dashboard through Parkland's Epic electronic health record system based on the inclusion/Exclusion criteria. Patients meeting criteria will be automatically flagged for study enrollment. No active consent will be required as the intervention involves standard communication methods already available to patients (MyChart and text messaging), and the study poses minimal risk.

Randomization and Crossover Design:

Patients will be randomized into one of two arms:

Control Arm (Usual Care): Patients receive standard hospital discharge instructions without additional messaging.

Intervention Arm: Patients receive structured follow-up messages using existing education materials via MyChart and automated text messaging within 24, 48, and 72 hours post-discharge. Patients in the control arm who experience a subsequent cancer treatment related ED visit without documented OAC engagement will be crossed over to the intervention arm.

Messaging Intervention:

Patients randomized to the intervention arm will receive structured follow-up messages aimed at increasing awareness and utilization of Oncology Acute Care (OAC) services. Messaging will be delivered via both MyChart and automated text messages, tailored to the patient's preferred language (English or Spanish).

  • Initial Message: Sent within 24 hours post discharge from the ED observation, or inpatient stay (10AM following discharge). This message will include:
  • Contact information for the OAC clinic and triage line
  • Guidance on when to seek urgent care through OAC versus emergency care, including a reminder that same-day OAC appointments may be available
  • Follow-Up Messages: If the initial message is not viewed, it will be resent at 48 hours and again at 72 hours post-discharge. Up to 3 messages will be sent per discharge.
  • Message Engagement Tracking: Once a message is viewed, the patient enters an outcome tracking period. The study team will record engagement metrics on whether messages were viewed to assess implementation fidelity.

Outcome Tracking:

The study team will monitor patient medical records for the following:

  • Time to next cancer treatment-related ED arrivals (including observation and inpatient admissions)
  • Contact with OAC clinic or triage line
  • Total hospital visits

Follow-up will occur in 3-month intervals. Patients who engage with the OAC clinic will be removed from the observation list and considered to have completed the study. If a patient has another ED visit without OAC engagement, the observation period will repeat.

Data Collection:

Data will be extracted from Epic and include:

  • Message engagement metrics (viewed/unviewed, response rates)
  • OAC contact logs
  • ED visit records
  • Patient demographics and clinical characteristics

Data Analysis Plan:

Descriptive statistics will be used to summarize engagement and outcome data. Time-to event analyses (Kaplan-Meier curves with Cox proportional hazards models) will be used to compare time to ED arrival between arms. Mixed-effects logistic regression will be used to analyze secondary visit county outcomes. Subgroup analyses will explore differential effects by language, cancer type, and prior ED utilization.

Conditions
Cancer
Being tested
Follow-up messaging
Keywords
Oncology Acute Care, Emergency Department Use, Messaging
Medical subject headings
Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Follow-up messagingOther

    Patients randomized to the intervention arm will receive structured follow-up messages aimed at increasing awareness and utilization of Oncology Acute Care (OAC) services. Messaging will be delivered via both MyChart and automated text messages, tailored to the patient's preferred language (English or Spanish).

Study groups in NCT07550192
Study groupRoleWhat they receive
Control Arm (Usual Care)No interventionPatients receive standard hospital discharge instructions without additional messaging Patients in the control arm who experience a subsequent cancer treatment-related ED visit without documented OAC engagement will be crossed over to the intervention arm.
Intervention ArmExperimentalPatients receive structured follow-up messages using existing education materials via MyChart and automated text messaging within 24, 48, and 72 hours post-discharge.
Receives: Other: Follow-up messaging

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to the next cancer treatment related ED visit.

    Evaluate whether structured MyChart + text messaging after hospital/ED discharge decreases time to the next cancer treatment-related ED visit compared with usual care.

    Measured: 2 years maximum

Secondary outcomes (4)
  1. Patient Engagement with OAC

    Assess whether messaging increases patient engagement with the Oncology Acute Care triage line or clinic before returning to the ED.

    Measured: 2 years maximum

  2. Message Engagement

    Measure message engagement metrics (viewed, unviewed, and response rates).

    Measured: 2 years maximum

  3. Evaluate Feasibility

    Evaluate feasibility and implementation fidelity of the messaging workflow within Parkland's Epic environment.

    Measured: 2 years maximum

  4. Identify Patient Subgroups

    Identify patient subgroups (e.g., language, cancer type, prior ED utilization) where the intervention has the greatest effect on ED utilization or care engagement.

    Measured: 2 years maximum

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2026
  2. Study start1 Sep 2026 (estimated)
  3. Primary completion1 Sep 2028 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07550192
Sponsor's protocol ID
STU20251326
Status last verified
Jul 2026
First submitted
17 Apr 2026
Last updated
4 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: We only plan to share aggregate data.

Questions about this trial

What is this clinical trial studying?

A study testing Follow-up messaging in people with Cancer, run by University of Texas Southwestern Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Arthur Hong, MD, MPH (214-648-3240, Arthur.Hong@utsouthwestern.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to the next cancer treatment related ED visit. (time frame: 2 years maximum). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in